Английская Википедия:Insulin degludec/insulin aspart

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Use American English Шаблон:Use dmy dates Шаблон:Infobox drug

Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus.[1][2][3][4] It contains insulin degludec and insulin aspart.[1] It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh.[1]

The most frequently reported side effect is hypoglycemia (low blood glucose levels).[1]

It was approved for medical use in the European Union in January 2013,[1] and in Australia in November 2017.[5]

Medical uses

Insulin degludec/insulin aspart is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of two years.[1]

Insulin degludec and insulin aspart are slightly different from human insulin.[1] The differences mean that insulin degludec is absorbed more slowly by the body.[1] This means it has a long duration of action.[1] Meanwhile, insulin aspart is absorbed faster by the body than human insulin, and therefore it starts to work as soon as it is injected and has a short duration of action.[1]

References

Шаблон:Reflist

External links

Шаблон:Oral hypoglycemics and insulin analogs Шаблон:Portal bar


Шаблон:Endocrine-disease-stub

  1. 1,0 1,1 1,2 1,3 1,4 1,5 1,6 1,7 1,8 1,9 Шаблон:Cite web Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. Шаблон:Cite journal
  3. Шаблон:Cite journal
  4. Шаблон:Cite journal
  5. Ошибка цитирования Неверный тег <ref>; для сносок Ryzodeg FlexTouch and Penfill AU PI не указан текст